{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:21:34Z","timestamp":1740126094192,"version":"3.37.3"},"reference-count":133,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000925","name":"Australian National Health and Medical Research Council Fellowships","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Melanoma Foundation of the University of Sydney"},{"name":"Deborah and John McMurtrie Melanoma Institute Australia Pathology Fellowship"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,1,17]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Although surgery for early-stage melanoma offers the best chance of cure, recent advances in molecular medicine have revolutionized the management of late-stage melanoma, leading to significant improvements in clinical outcomes. Research into the genomic drivers of disease and cancer immunology has not only ushered in a new era of targeted and immune-based therapies for patients with metastatic melanoma, but has also provided new tools for monitoring disease recurrence and selecting therapeutic strategies. These advances present new opportunities and challenges to the surgeon treating patients with melanoma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The literature was reviewed to evaluate diagnostic and therapeutic advances in the management of cutaneous melanoma, and to highlight the impact of these advances on surgical decision-making.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Genomic testing is not required in the surgical management of primary melanoma, although it can provide useful information in some situations. Circulating nucleic acids from melanoma cells can be detected in peripheral blood to predict disease recurrence before it manifests clinically, but validation is required before routine clinical application. BRAF mutation testing is the standard of care for all patients with advanced disease to guide therapy, including the planning of surgery in adjuvant and neoadjuvant settings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Surgery remains central for managing primary melanoma, and is an important element of integrated multidisciplinary care in advanced disease, particularly for patients with resectable metastases. The field will undergo further change as clinical trials address the relationships between surgery, radiotherapy and systemic therapy for patients with high-risk, early-stage and advanced melanoma.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bjs.10751","type":"journal-article","created":{"date-parts":[[2018,1,17]],"date-time":"2018-01-17T11:43:20Z","timestamp":1516189400000},"page":"e31-e47","source":"Crossref","is-referenced-by-count":3,"title":["Impact of genomics on the surgical management of melanoma"],"prefix":"10.1093","volume":"105","author":[{"given":"P M","family":"Ferguson","sequence":"first","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G V","family":"Long","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Medical Oncology, Royal North Shore Hospital, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R A","family":"Scolyer","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J F","family":"Thompson","sequence":"additional","affiliation":[{"name":"Melanoma Institute Australia, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia"},{"name":"Department of Melanoma and Surgical Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2018,1,17]]},"reference":[{"key":"2021020617172670200_bjs10751-bib-0001","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.critrevonc.2015.12.002","article-title":"The rapidly evolving therapies for advanced melanoma \u2013 towards immunotherapy, molecular targeted therapy, and beyond","volume":"99","author":"Zhu","year":"2016","journal-title":"Crit Rev Oncol Hematol"},{"key":"2021020617172670200_bjs10751-bib-0002","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pathol.2015.12.011","article-title":"Advances in melanoma: revolutionary progress delivering improved patient management and outcomes","volume":"48","author":"Scolyer","year":"2016","journal-title":"Pathology"},{"key":"2021020617172670200_bjs10751-bib-0003","doi-asserted-by":"crossref","first-page":"6199","DOI":"10.1200\/JCO.2009.23.4799","article-title":"Final version of 2009 AJCC melanoma staging and classification","volume":"27","author":"Balch","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0004","first-page":"2170","article-title":"Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization","volume":"58","author":"Bastian","year":"1998","journal-title":"Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0005","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1056\/NEJMoa1502583","article-title":"The genetic evolution of melanoma from precursor lesions","volume":"373","author":"Shain","year":"2015","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/S1525-1578(10)60684-8","article-title":"Molecular aspects of melanocytic dysplastic nevi","volume":"4","author":"Hussein","year":"2002","journal-title":"J Mol Diagn"},{"key":"2021020617172670200_bjs10751-bib-0007","article-title":"Atypical Spitz nevi: a case report and review of the literature","volume":"15","author":"Filiberto","year":"2015","journal-title":"Eplasty"},{"key":"2021020617172670200_bjs10751-bib-0008","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/modpathol.2016.70","article-title":"diagnostic algorithm for atypical spitzoid tumors: guidelines for immunohistochemical and molecular assessment","volume":"29","author":"Cho-Vega","year":"2016","journal-title":"Mod Pathol"},{"key":"2021020617172670200_bjs10751-bib-0009","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/PAS.0b013e31822d5ff8","article-title":"Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an adjunctive probe","volume":"36","author":"Gammon","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"2021020617172670200_bjs10751-bib-0010","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1016\/S0002-9440(10)63536-5","article-title":"Classifying melanocytic tumors based on DNA copy number changes","volume":"163","author":"Bastian","year":"2003","journal-title":"Am J Pathol"},{"key":"2021020617172670200_bjs10751-bib-0011","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jmoldx.2013.04.001","article-title":"A genome-wide high-resolution array-CGH analysis of cutaneous melanoma and comparison of array-CGH to FISH in diagnostic evaluation","volume":"15","author":"Wang","year":"2013","journal-title":"J Mol Diagn"},{"key":"2021020617172670200_bjs10751-bib-0012","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1097\/PAS.0b013e3182753de6","article-title":"Risk assessment for atypical spitzoid melanocytic neoplasms using FISH to identify chromosomal copy number aberrations","volume":"37","author":"Gerami","year":"2013","journal-title":"Am J Surg Pathol"},{"key":"2021020617172670200_bjs10751-bib-0013","article-title":"TERT promoter mutations are predictive of aggressive clinical behavior in patients with spitzoid melanocytic neoplasms","volume":"5","author":"Lee","year":"2015","journal-title":"Sci Rep"},{"key":"2021020617172670200_bjs10751-bib-0014","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1136\/jclinpath-2014-202404","article-title":"Guidance for laboratories performing molecular pathology for cancer patients","volume":"67","author":"Cree","year":"2014","journal-title":"J Clin Pathol"},{"key":"2021020617172670200_bjs10751-bib-0015","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/jid.2014.452","article-title":"More people die from thin melanomas (\u2264 1 mm) than from thick melanomas (&gt; 4 mm) in Queensland, Australia","volume":"135","author":"Whiteman","year":"2015","journal-title":"J Invest Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0016","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2016.10.018","article-title":"Mortality burden and prognosis of thin melanomas overall and by subcategory of thickness, SEER registry data, 1992\u20132013","volume":"76","author":"Landow","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0017","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1038\/jid.2008.347","article-title":"MicroRNA expression in melanocytic nevi: the usefulness of formalin-fixed, paraffin-embedded material for miRNA microarray profiling","volume":"129","author":"Glud","year":"2009","journal-title":"J Invest Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0018","doi-asserted-by":"crossref","first-page":"2456","DOI":"10.1158\/0008-5472.CAN-06-2698","article-title":"Characterization of microRNA expression levels and their biological correlates in human cancer cell lines","volume":"67","author":"Gaur","year":"2007","journal-title":"Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0019","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1038\/jid.2010.63","article-title":"MicroRNA expression profiles associated with mutational status and survival in malignant melanoma","volume":"130","author":"Caramuta","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/modpathol.2015.149","article-title":"microRNA-10b is a prognostic biomarker for melanoma","volume":"29","author":"Saldanha","year":"2016","journal-title":"Mod Pathol"},{"key":"2021020617172670200_bjs10751-bib-0021","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1158\/1078-0432.CCR-09-2721","article-title":"Melanoma microRNA signature predicts post-recurrence survival","volume":"16","author":"Segura","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0022","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1158\/1078-0432.CCR-13-3316","article-title":"Development of a prognostic genetic signature to predict the metastatic risk associated with cutaneous melanoma","volume":"21","author":"Gerami","year":"2015","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0023","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/j.mayocp.2016.05.012","article-title":"Gene expression profiling in cutaneous melanoma: caveats for clinicians","volume":"91","author":"Sominidi-Damodaran","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"2021020617172670200_bjs10751-bib-0024","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1365-2559.1990.tb00758.x","article-title":"Epidermal melanocytes adjacent to melanoma and the field change effect","volume":"17","author":"Fallowfield","year":"1990","journal-title":"Histopathology"},{"key":"2021020617172670200_bjs10751-bib-0025","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00000372-199606000-00002","article-title":"Melanocytic hyperplasia in scars. A histopathological investigation of 722 cases","volume":"18","author":"Duve","year":"1996","journal-title":"Am J Dermatopathol"},{"key":"2021020617172670200_bjs10751-bib-0026","first-page":"1968","article-title":"Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin","volume":"60","author":"Bastian","year":"2000","journal-title":"Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0027","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1529-8019.2005.00049.x","article-title":"Cutaneous melanoma: surveillance of patients for recurrence and new primary melanomas","volume":"18","author":"Benvenuto-Andrade","year":"2005","journal-title":"Dermatol Ther"},{"key":"2021020617172670200_bjs10751-bib-0028","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0057665","article-title":"Hazard-rate analysis and patterns of recurrence in early stage melanoma: moving towards a rationally designed surveillance strategy","volume":"8","author":"Salama","year":"2013","journal-title":"PLoS One"},{"key":"2021020617172670200_bjs10751-bib-0029","first-page":"18","article-title":"A global review of melanoma follow-up guidelines","volume":"6","author":"Trotter","year":"2013","journal-title":"J Clin Aesthet Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0030","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"2021020617172670200_bjs10751-bib-0031","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0085004","article-title":"Inter- and intra-patient heterogeneity of response and progression to targeted therapy in metastatic melanoma","volume":"9","author":"Menzies","year":"2014","journal-title":"PLoS One"},{"key":"2021020617172670200_bjs10751-bib-0032","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cll.2011.03.007","article-title":"Sentinel lymph nodes in cutaneous melanoma","volume":"31","author":"Prieto","year":"2011","journal-title":"Clin Lab Med"},{"key":"2021020617172670200_bjs10751-bib-0033","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","article-title":"Completion dissection or observation for sentinel-node metastasis in melanoma","volume":"376","author":"Faries","year":"2017","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0034","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1097\/00000478-199607000-00006","article-title":"Nodal nevi and cutaneous melanomas","volume":"20","author":"Carson","year":"1996","journal-title":"Am J Surg Pathol"},{"key":"2021020617172670200_bjs10751-bib-0035","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.2005.03.2342","article-title":"Prospective multi-institutional study of reverse transcriptase polymerase chain reaction for molecular staging of melanoma","volume":"24","author":"Scoggins","year":"2006","journal-title":"J Clin Oncol"},{"volume-title":"AJCC Cancer Staging Manual","year":"2016","author":"Amin","key":"2021020617172670200_bjs10751-bib-0036"},{"key":"2021020617172670200_bjs10751-bib-0037","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1097\/CMR.0b013e32831993cc","article-title":"Prospective monitoring of adjuvant treatment in high-risk melanoma patients: lactate dehydrogenase and protein S-100B as indicators of relapse","volume":"19","author":"Egberts","year":"2009","journal-title":"Melanoma Res"},{"key":"2021020617172670200_bjs10751-bib-0038","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/S0190-9622(99)70254-9","article-title":"S-100 protein in peripheral blood: a marker for melanoma metastases: a prospective 2-center study of 570 patients with melanoma","volume":"41","author":"Kaskel","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0039","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.canlet.2006.12.014","article-title":"Circulating tumor cells (CTC) detection: clinical impact and future directions","volume":"253","author":"Paterlini-Brechot","year":"2007","journal-title":"Cancer Lett"},{"key":"2021020617172670200_bjs10751-bib-0040","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s40291-013-0071-2","article-title":"Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential","volume":"18","author":"Mumford","year":"2014","journal-title":"Mol Diagn Ther"},{"key":"2021020617172670200_bjs10751-bib-0041","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(02)09838-0","article-title":"Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer","volume":"360","author":"Klein","year":"2002","journal-title":"Lancet"},{"key":"2021020617172670200_bjs10751-bib-0042","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1373\/clinchem.2004.045096","article-title":"Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients","volume":"51","author":"Koyanagi","year":"2005","journal-title":"Clin Chem"},{"key":"2021020617172670200_bjs10751-bib-0043","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canlet.2017.06.030","article-title":"Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma","volume":"404","author":"Calapre","year":"2017","journal-title":"Cancer Lett"},{"key":"2021020617172670200_bjs10751-bib-0044","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1158\/2159-8290.CD-15-1336","article-title":"Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma","volume":"6","author":"Girotti","year":"2016","journal-title":"Cancer Discov"},{"key":"2021020617172670200_bjs10751-bib-0045","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1093\/annonc\/mdx026","article-title":"Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma","volume":"28","author":"Lee","year":"2017","journal-title":"Ann Oncol"},{"key":"2021020617172670200_bjs10751-bib-0046","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.5788","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","journal-title":"Oncotarget"},{"key":"2021020617172670200_bjs10751-bib-0047","first-page":"13","article-title":"Diagnostic and prognostic biomarkers in melanoma","volume":"7","author":"Weinstein","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0048","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"2021020617172670200_bjs10751-bib-0049","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.cell.2012.06.024","article-title":"A landscape of driver mutations in melanoma","volume":"150","author":"Hodis","year":"2012","journal-title":"Cell"},{"key":"2021020617172670200_bjs10751-bib-0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"2021020617172670200_bjs10751-bib-0051","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1056\/NEJMoa050092","article-title":"Distinct sets of genetic alterations in melanoma","volume":"353","author":"Curtin","year":"2005","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0052","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic classification of cutaneous melanoma","volume":"161","author":"Cancer Genome Atlas Network","year":"2015","journal-title":"Cell"},{"key":"2021020617172670200_bjs10751-bib-0053","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"2021020617172670200_bjs10751-bib-0054","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.pathol.2015.12.002","article-title":"Melanoma progression","volume":"48","author":"Elder","year":"2016","journal-title":"Pathology"},{"key":"2021020617172670200_bjs10751-bib-0055","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc.2016.37","article-title":"From melanocytes to melanomas","volume":"16","author":"Shain","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"2021020617172670200_bjs10751-bib-0056","doi-asserted-by":"crossref","first-page":"41 017","DOI":"10.18632\/oncotarget.9351","article-title":"NRAS and EPHB6 mutation rates differ in metastatic melanomas of patients in the North Island versus South Island of New Zealand","volume":"7","author":"Jones","year":"2016","journal-title":"Oncotarget"},{"key":"2021020617172670200_bjs10751-bib-0057","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S1470-2045(17)30180-8","article-title":"Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Dummer","year":"2017","journal-title":"Lancet Oncol"},{"key":"2021020617172670200_bjs10751-bib-0058","doi-asserted-by":"crossref","first-page":"9009","DOI":"10.1200\/jco.2014.32.15_suppl.9009","article-title":"A phase 1b\/2 study of LEE011 in combination with binimetinib (MEK162) in patients with NRAS-mutant melanoma: early encouraging clinical activity","volume":"32","author":"Sosman","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0059","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1001\/jama.2011.746","article-title":"KIT as a therapeutic target in metastatic melanoma","volume":"305","author":"Carvajal","year":"2011","journal-title":"JAMA"},{"key":"2021020617172670200_bjs10751-bib-0060","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/annonc\/mdx079","article-title":"Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial","volume":"28","author":"Guo","year":"2017","journal-title":"Ann Oncol"},{"key":"2021020617172670200_bjs10751-bib-0061","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1056\/NEJMoa1112302","article-title":"Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib","volume":"366","author":"Sosman","year":"2012","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0062","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1056\/NEJMoa1103782","article-title":"Improved survival with vemurafenib in melanoma with BRAF V600E mutation","volume":"364","author":"Chapman","year":"2011","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0063","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/S0140-6736(12)60868-X","article-title":"Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial","volume":"380","author":"Hauschild","year":"2012","journal-title":"Lancet"},{"key":"2021020617172670200_bjs10751-bib-0064","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0065","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0066","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0067","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1016\/S1470-2045(16)30578-2","article-title":"Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials","volume":"17","author":"Long","year":"2016","journal-title":"Lancet Oncol"},{"key":"2021020617172670200_bjs10751-bib-0068","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nature08833","article-title":"RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth","volume":"464","author":"Hatzivassiliou","year":"2010","journal-title":"Nature"},{"key":"2021020617172670200_bjs10751-bib-0069","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1755-148X.2010.00685.x","article-title":"PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells","volume":"23","author":"Halaban","year":"2010","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021020617172670200_bjs10751-bib-0070","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet."},{"key":"2021020617172670200_bjs10751-bib-0071","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1200\/JCO.2015.62.9345","article-title":"Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib","volume":"34","author":"Long","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0072","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.ejca.2012.11.019","article-title":"Resistance to BRAF-targeted therapy in melanoma","volume":"49","author":"Sullivan","year":"2013","journal-title":"Eur J Cancer"},{"key":"2021020617172670200_bjs10751-bib-0073","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(14)70110-X","article-title":"Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study","volume":"15","author":"Corrie","year":"2014","journal-title":"Lancet Oncol"},{"key":"2021020617172670200_bjs10751-bib-0074","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1158\/1078-0432.CCR-13-1551","article-title":"Molecular pathways: CDK4 inhibitors for cancer therapy","volume":"20","author":"Dickson","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0075","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1158\/1078-0432.CCR-11-2381","article-title":"The clinical effect of the dual-targeting strategy involving PI3K\/AKT\/mTOR and RAS\/MEK\/ERK pathways in patients with advanced cancer","volume":"18","author":"Shimizu","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0076","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CMR.0b013e32832eabd5","article-title":"Spontaneous regression of metastases from melanoma: review of the literature","volume":"19","author":"Kalialis","year":"2009","journal-title":"Melanoma Res"},{"key":"2021020617172670200_bjs10751-bib-0077","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejso.2013.09.026","article-title":"Spontaneous regression of metastatic melanoma \u2013 clinical evidence of the abscopal effect","volume":"40","author":"Bramhall","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"2021020617172670200_bjs10751-bib-0078","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1097\/00002371-199807000-00005","article-title":"Tumor cells induce cytolytic T cells to a single immunodominant mutant peptide","volume":"21","author":"Dubey","year":"1998","journal-title":"J Immunother"},{"key":"2021020617172670200_bjs10751-bib-0079","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1200\/JCO.2007.11.9941","article-title":"Phase III comparison of vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 Study Group","volume":"26","author":"Testori","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0080","doi-asserted-by":"crossref","first-page":"5188","DOI":"10.4049\/jimmunol.170.10.5188","article-title":"A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen","volume":"170","author":"Gold","year":"2003","journal-title":"J Immunol"},{"key":"2021020617172670200_bjs10751-bib-0081","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-12-0704","article-title":"Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma","volume":"18","author":"Hunn","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0082","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/CJI.0b013e31817d2f45","article-title":"Allogeneic melanoma vaccine expressing alphaGal epitopes induces antitumor immunity to autologous antigens in mice without signs of toxicity","volume":"31","author":"Rossi","year":"2008","journal-title":"J Immunother"},{"key":"2021020617172670200_bjs10751-bib-0083","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1084\/jem.20012100","article-title":"Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells","volume":"195","author":"Schuler-Thurner","year":"2002","journal-title":"J Exp Med"},{"key":"2021020617172670200_bjs10751-bib-0084","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.clindermatol.2012.08.005","article-title":"Vaccines against advanced melanoma","volume":"31","author":"Blanchard","year":"2013","journal-title":"Clin Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0085","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.smim.2008.09.006","article-title":"Antigens for cancer immunotherapy","volume":"20","author":"Neller","year":"2008","journal-title":"Semin Immunol"},{"key":"2021020617172670200_bjs10751-bib-0086","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1146\/annurev-med-060512-150254","article-title":"Chimeric antigen receptor therapy for cancer","volume":"65","author":"Barrett","year":"2014","journal-title":"Annu Rev Med"},{"key":"2021020617172670200_bjs10751-bib-0087","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2013 elimination, equilibrium and escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr Opin Immunol"},{"key":"2021020617172670200_bjs10751-bib-0088","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0089","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.seminoncol.2012.01.006","article-title":"Advances in the treatment of metastatic melanoma: adoptive T-cell therapy","volume":"39","author":"Bernatchez","year":"2012","journal-title":"Semina Oncol"},{"key":"2021020617172670200_bjs10751-bib-0090","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0091","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/mt.2014.160","article-title":"CTLA-4 and PD-L1 checkpoint blockade enhances oncolytic measles virus therapy","volume":"22","author":"Engeland","year":"2014","journal-title":"Mol Ther"},{"key":"2021020617172670200_bjs10751-bib-0092","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0093","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0094","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0095","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1073\/pnas.0915174107","article-title":"PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors","volume":"107","author":"Curran","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021020617172670200_bjs10751-bib-0096","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0097","doi-asserted-by":"crossref","first-page":"171520","DOI":"10.1155\/2015\/171520","article-title":"Glucocorticoid-induced tumour necrosis factor receptor-related protein: a key marker of functional regulatory T cells","volume":"2015","author":"Ronchetti","year":"2015","journal-title":"J Immunol Res"},{"key":"2021020617172670200_bjs10751-bib-0098","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejca.2016.06.028","article-title":"Rationale for anti-GITR cancer immunotherapy","volume":"67","author":"Knee","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021020617172670200_bjs10751-bib-0099","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12916-016-0571-0","article-title":"Advances in immunotherapy for melanoma","volume":"14","author":"Redman","year":"2016","journal-title":"BMC Med"},{"key":"2021020617172670200_bjs10751-bib-0100","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.2217\/imt.15.87","article-title":"Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"7","author":"Abdel-Rahman","year":"2015","journal-title":"Immunotherapy"},{"key":"2021020617172670200_bjs10751-bib-0101","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (AEs) of anti-programmed cell death (PD)-1 therapy in patients with metastatic melanoma: a single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2021020617172670200_bjs10751-bib-0102","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s40425-016-0199-9","article-title":"Sarcoidosis in the setting of combination ipilimumab and nivolumab immunotherapy: a case report and review of the literature","volume":"4","author":"Reuss","year":"2016","journal-title":"J Immunother Cancer"},{"key":"2021020617172670200_bjs10751-bib-0103","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2016.02.001","article-title":"Management of toxicities of immune checkpoint inhibitors","volume":"44","author":"Spain","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"2021020617172670200_bjs10751-bib-0104","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1210\/jc.2012-4075","article-title":"Endocrine side effects induced by immune checkpoint inhibitors","volume":"98","author":"Corsello","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2021020617172670200_bjs10751-bib-0105","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1200\/JCO.2013.53.0105","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0106","doi-asserted-by":"crossref","first-page":"CT001","DOI":"10.1158\/1538-7445.AM2016-CT001","article-title":"Abstract CT001: Durable, long-term survival in previously treated patients with advanced melanoma (MEL) who received nivolumab (NIVO) monotherapy in a phase I trial","volume":"76","author":"Hodi","year":"2016","journal-title":"Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0107","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13045-016-0277-y","article-title":"Current status and perspectives in translational biomarker research for PD-1\/PD-L1 immune checkpoint blockade therapy","volume":"9","author":"Ma","year":"2016","journal-title":"J Hematol Oncol"},{"key":"2021020617172670200_bjs10751-bib-0108","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070826","article-title":"Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing","volume":"8","author":"Boursault","year":"2013","journal-title":"PLoS One"},{"key":"2021020617172670200_bjs10751-bib-0109","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient homogeneity of BRAFV600E expression in melanoma","volume":"38","author":"Menzies","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"2021020617172670200_bjs10751-bib-0110","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/dc.22820","article-title":"The role of cytology specimens in molecular testing of solid tumors: techniques, limitations, and opportunities","volume":"40","author":"Aisner","year":"2012","journal-title":"Diagn Cytopathol"},{"key":"2021020617172670200_bjs10751-bib-0111","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/his.12992","article-title":"BRAF(V600E) and NRAS(Q61L\/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting","volume":"69","author":"Kakavand","year":"2016","journal-title":"Histopathology"},{"key":"2021020617172670200_bjs10751-bib-0112","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0113","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.pathol.2015.12.008","article-title":"The molecular profile of metastatic melanoma in Australia","volume":"48","author":"Lyle","year":"2016","journal-title":"Pathology"},{"key":"2021020617172670200_bjs10751-bib-0114","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/MB:26:2:147","article-title":"MALDI-TOF mass spectrometry: a versatile tool for high-performance DNA analysis","volume":"26","author":"Jurinke","year":"2004","journal-title":"Mol Biotechnol"},{"key":"2021020617172670200_bjs10751-bib-0115","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-13-3271","article-title":"Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy","volume":"20","author":"Taube","year":"2014","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0116","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"2021020617172670200_bjs10751-bib-0117","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/annonc\/mdw379.07","article-title":"PD-L1 expression as a biomarker for nivolumab (NIVO) plus ipilimumab (IPI) and NIVO alone in advanced melanoma (MEL): a pooled analysis","volume":"27","author":"Long","year":"2016","journal-title":"Ann Oncol"},{"key":"2021020617172670200_bjs10751-bib-0118","doi-asserted-by":"crossref","first-page":"CT004","DOI":"10.1158\/1538-7445.AM2016-CT004","article-title":"Abstract CT004: KEYNOTE-006: PD-L1 expression and efficacy in patients (Pts) treated with pembrolizumab (pembro) vs ipilimumab (IPI) for advanced melanoma","volume":"76","author":"Carlino","year":"2016","journal-title":"Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0119","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/pcmr.12503","article-title":"Residual FDG-PET metabolic activity in metastatic melanoma patients with prolonged response to anti-PD-1 therapy","volume":"29","author":"Kong","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"2021020617172670200_bjs10751-bib-0120","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/PPO.0000000000000243","article-title":"Clinical trial design and endpoints for stage IV melanoma in the modern era","volume":"23","author":"Izar","year":"2017","journal-title":"Cancer J"},{"key":"2021020617172670200_bjs10751-bib-0121","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2017.1588","article-title":"Nivolumab for patients with advanced melanoma treated beyond progression: analysis of 2 phase 3 clinical trials","volume-title":"JAMA Oncol","author":"Long","year":"2017"},{"key":"2021020617172670200_bjs10751-bib-0122","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/1078-0432.CCR-09-1624","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021020617172670200_bjs10751-bib-0123","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1097\/PPO.0b013e31824bc981","article-title":"Surgery for distant melanoma metastasis","volume":"18","author":"Leung","year":"2012","journal-title":"Cancer J"},{"key":"2021020617172670200_bjs10751-bib-0124","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"},{"key":"2021020617172670200_bjs10751-bib-0125","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","article-title":"Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy","volume":"375","author":"Eggermont","year":"2016","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0126","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12916-017-0826-4","article-title":"News from the melanoma sessions of the European Cancer Congress 2017","volume":"15","author":"Rutkowski","year":"2017","journal-title":"BMC Med"},{"key":"2021020617172670200_bjs10751-bib-0127","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume-title":"N Engl J Med","author":"Weber","year":"2017"},{"key":"2021020617172670200_bjs10751-bib-0128","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"key":"2021020617172670200_bjs10751-bib-0129","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.9583","article-title":"Phase 2 study of neoadjuvant dabrafenib + trametinib (D+T) for resectable stage IIIb\/c BRAF-V600 mutation positive melanoma","volume-title":"J Clin Oncol","author":"Saw","year":"2016"},{"key":"2021020617172670200_bjs10751-bib-0130","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/S0959-8049(17)30485-9","article-title":"Meulen Ter S et al. 1146 \u2013 Downsizing of locally advanced stage III (bulky) BRAF V600E\/K melanoma with combination targeted therapy to achieve R0 resection","volume":"72","author":"Haanen","year":"2017","journal-title":"Eur J Cancer"},{"key":"2021020617172670200_bjs10751-bib-0131","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/01.COT.0000469384.44361.3e","article-title":"Dabrafenib\u2013trametinib combo also has activity in lung cancer","volume":"37","author":"Fuerst","year":"2015","journal-title":"Oncology Times"},{"key":"2021020617172670200_bjs10751-bib-0132","doi-asserted-by":"crossref","first-page":"9586","DOI":"10.1200\/JCO.2017.35.15_suppl.9586","article-title":"Neoadjuvant ipilimumab + nivolumab (IPI + NIVO) in palpable stage III melanoma: updated data from the OpACIN trial and first immunological analyses","volume":"35","author":"Rozeman","year":"2017","journal-title":"J Clin Oncol"},{"key":"2021020617172670200_bjs10751-bib-0133","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms15618","article-title":"DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity","volume":"8","author":"Vanpouille-Box","year":"2017","journal-title":"Nat Commun"}],"container-title":["British Journal of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbjs.10751","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/105\/2\/e31\/36206662\/bjs10751.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/bjs\/article-pdf\/105\/2\/e31\/36206662\/bjs10751.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T18:49:02Z","timestamp":1660330142000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjs\/article\/105\/2\/e31-e47\/6123095"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":133,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2018,1,17]]},"published-print":{"date-parts":[[2018,1,17]]}},"URL":"https:\/\/doi.org\/10.1002\/bjs.10751","relation":{},"ISSN":["0007-1323","1365-2168"],"issn-type":[{"type":"print","value":"0007-1323"},{"type":"electronic","value":"1365-2168"}],"subject":[],"published-other":{"date-parts":[[2018,1]]},"published":{"date-parts":[[2018,1]]}}}